Oesophagectomy for tumours and dysplasia of the oesophagus and gastro-oesophageal junction

ANZ Journal of Surgery

Volumn 79, Issue 4, 2009, Pages 251-257

  Epari, Krishna ^a   Cade, Richard ^a,b,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b BOX HILL HOSPITAL   (Australia)

^c Epworth Eastern Medical Centre   (Australia)

Author keywords

Lymph node excision; Neoadjuvant therapy; Oesophageal neoplasms; Oesophagectomy

Indexed keywords

ADULT; AGED; ANASTOMOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DYSPLASIA; ENDOSCOPIC ECHOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; ESOPHAGUS SURGERY; ESOPHAGUS TUMOR; FEMALE; HUMAN; HUMAN TISSUE; LAPAROSCOPY; LENGTH OF STAY; LOWER ESOPHAGUS SPHINCTER; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PROSPECTIVE STUDY; SURGICAL TECHNIQUE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BARRETT ESOPHAGUS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL DISEASES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; ESOPHAGUS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 65349101630     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2009.04855.x     Document Type: Article

References (26)

1. O'Rourke I, Tait N, Bull C, Gebski V, Holland M, Johnson DC. Oesophageal cancer: outcome of modern surgical management. ANZ J. Surg. 1995 65 : 11 16.
2. Griffiths EA, Pritchard SA, Mapstone NP, Welch IM. Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology: an update for the surgical oncologist. World J. Surg. Oncol. 2006 21 : 82 98.
3. Burmeister B, Smithers BM, Gebski V et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005 6 : 659 68.
4. Jamieson GG, Mathew G, Ludemann R, Wayman J, Myers JC, Devitt PG. Postoperative mortality following oesophagectomy and problems in reporting its rate. Br. J. Surg. 2004 91 : 943 7.
5. Metzger R, Bollschweiler E, Vallbohmer D et al. High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality? Dis. Esophagus 2004 17 : 310 14.
6. Dimick JB, Pronovost PJ, Cowan MD, Lipsett PA. Surgical volume and quality of care for esophageal resection: do high-volume hospitals have fewer complications? Ann. Thorac. Surg. 2003 75 : 337 41.
7. Urbach DR, Baxter NN. Does it matter what a hospital is "high volume" for? Specificity of hospital volume outcome associations for surgical procedures: analysis of administrative data. Qual. Saf. Health Care 2004 13 : 379 83.
8. Allum WH, Griffin SM, Watson A et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2002 50 (Suppl. V v1 v23.
9. Gebski V, Burmeister B, Smithers BM et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007 8 : 226 34.
10. Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomised controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am. J. Surg. 2002 183 : 274 9.
11. Urshel JD, Vasan H. A meta-analysis of randomised controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am. J. Surg. 2003 185 : 538 43.
12. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann. Surg. Oncol. 2003 10 : 754 61.
13. Fiorica F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004 53 : 925 30.
14. Greer SE, Goodney PP, Sutton JE, Birkmeyer JD. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 2005 137 : 172 7.
15. Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother. Oncol. 2006 78 : 236 44.
16. Malthaner RA, Collin S, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst. Rev. 2006 3 CD001556.
17. Graham AJ, Shrive FM, Ghali WA et al. Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. Ann. Thorac. Surg. 2007 83 : 1257 64.
18. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006 355 : 11 20.
19. Zhang X, Watson DI, Jamieson GG, Lally C, Bessell JR, Devitt PG. Outcome of oesophagectomy for adenocarcinoma of the oesophagus and oesophagogastric junction. ANZ J. Surg. 2005 75 : 513 19.
20. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N. Engl. J. Med. 1985 313 : 1291 2.
21. Kalade AV, Desmond PV, Chen RY. Experience of endoscopic ultrasound in an Australian tertiary hospital. ANZ J. Surg. 2006 76 : 1075 80.
22. Altorki N, Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann. Surg. 2001 234 : 581 7.
23. D'Journo XB, Doddoli C, Michelet P et al. Transthoracic esophagectomy for adenocarcinoma of the oesophagus: standard versus extended two-field mediastinal lymphadenectomy? Eur. J. Cardiothorac. Surg. 2005 27 : 697 704.
24. Bonnenkamp JJ, Hermans J, Sasako M et al. Extended lymph node dissection for gastric cancer. N. Engl. J. Med. 1999 340 : 908 14.
25. Cuschieri A, Fayers P, Fielding J et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet 1996 347 : 995 9.
26. Law S, Wong J. Lymph node dissection in surgical treatment of esophageal neoplasms. Surg. Oncol. Clin. N. Am. 2007 16 : 115 31.